Loading news...
PTC launches cloud-native MBD in Onshape, embedding manufacturing data into 3D models to streamline design, boost collaboration and speed production.
BOSTON, Feb. 27, 2026 /PRNewswire/ -- PTC (Nasdaq: PTC) today announced that it will participate in the following conferences. What: KeyBanc Capital Markets Emerging Technology Summit When: 1x1's on Tuesday, March 3, 2026 What: Morgan Stanley Technology, Media & Telecom Conference When: Wednesday, March 4, 2026 at 4:05pm PST What: BofA Securities 33rd Annual Industrials, Transportation & Airlines Key Leaders Conference When: 1x1's on Tuesday, May 12, 2026 What: J.P.
Introduces the only cloud-native MBD capability built into the core modeling experience, fully integrated within CAD and PDM Creates a single, always-up-to-date product definition by embedding manufacturing information directly in the live 3D model Improves collaboration and change control across engineering and manufacturing BOSTON, Feb. 26, 2026 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced the release of a fully cloud-native Model-Based Definition (MBD) capability, built directly into its Onshape® computer-aided design (CAD) and product data management (PDM) platform. The new capability allows engineering teams to add manufacturing information directly into the 3D model early in the design process, enabling clearer design intent, fewer handoffs, and improved efficiency across design, documentation, manufacturing, and quality.
WARREN, N.J., Feb. 23, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: TD Cowen 46th Annual Health Care Conference 2026 Monday, March 2 at 9:50 a.m.
PTC Therapeutics is transitioning its growth engine from legacy drugs to new launches like Sephience, targeting rare genetic diseases with high unmet need. Pipeline catalysts, notably Votoplam for Huntington's disease and Vatiquinone for Friedreich's ataxia, offer significant upside but carry clinical trial risks. PTCT's competitive edge lies in its oral small molecule platform, collaborative development model, and strong pricing power in ultra-rare disease markets.
Aurora Investment Counsel decreased its position in PTC Inc. (NASDAQ: PTC) by 70.5% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,395 shares of the technology company's stock after selling 5,716 shares during the quarter. Aurora Investment Counsel's holdings in PTC
AI is an opportunity, not a threat, for PTC's business model, and growth in its key metric is set to rebound in the near future. The stock's valuation hasn't been this cheap in a decade.
– Full-year 2025 product and royalty revenue of $831M, exceeding guidance – – Strong Sephience™ (sepiapterin) uptake since 2H 2025 launch with fourth quarter and 2025 revenue of $92M and $111M, respectively – – Cash of $1.95B as of December 31, 2025 – WARREN, N.J., Feb. 19, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December 31, 2025.
Skandinaviska Enskilda Banken AB publ lifted its stake in PTC Inc. (NASDAQ: PTC) by 8.0% in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 90,828 shares of the technology company's stock after purchasing an additional 6,724 shares during the quarter. Skandinaviska
WARREN, N.J., Feb. 12, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has withdrawn the New Drug Application (NDA) resubmission for Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (DMD) following U.S. Food and Drug Administration (FDA) feedback on the application review.
Addresses performance, data consistency, and workflow challenges that slow product development and impact downstream teams Enables faster, more collaborative product execution with a cloud-based PLM solution built to support future growth BOSTON, Feb. 12, 2026 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced that SPG Company, a global leader in licensed product design, development, manufacturing, and distribution, has selected PTC's FlexPLM® retail product lifecycle management (PLM) solution to modernize and support its end-to-end product lifecycle operations. With FlexPLM, SPG will replace its legacy PLM system with a scalable, cloud-based platform designed to support faster development cycles and more consistent product data.
Drake and Associates LLC purchased a new position in shares of PTC Inc. (NASDAQ: PTC) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 9,647 shares of the technology company's stock, valued at approximately $1,833,000. Other hedge funds have also made
Code Rebel (OTCMKTS:CDRBQ - Get Free Report) and PTC (NASDAQ: PTC - Get Free Report) are both computer and technology companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership and profitability. Institutional and Insider Ownership 95.1% of PTC
PTC (NASDAQ: PTC) executives said the company delivered a "solid" start to fiscal 2026, pointing to steady annual recurring revenue (ARR) growth, expanding free cash flow, and what they described as improving demand capture tied to its "Intelligent Product Lifecycle" strategy. On the company's fiscal first-quarter earnings call, CEO Neil Barua said PTC grew constant-currency ARR
PTC's Q1 FY26 EPS surges 75% Y/Y to $1.92 and revenues jump 21%, beating guidance and consensus while IPL strategy and large deals gain traction.
WARREN, N.J., Feb. 5, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its fourth quarter and full year 2025 financial results and provide an update on the company's business and outlook on Thursday, Feb. 19, 2026, at 4:30 p.m.
PTC Inc. (PTC) Q1 2026 Earnings Call Transcript
Although the revenue and EPS for PTC Inc. (PTC) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
PTC Inc. (PTC) came out with quarterly earnings of $1.92 per share, beating the Zacks Consensus Estimate of $1.59 per share. This compares to earnings of $1.1 per share a year ago.
Strategic focus on Intelligent Product Lifecycle vision Solid execution in Q1'26 Constant currency ARR growth of 8.4%; 9.0% excluding Kepware and ThingWorx Operating and free cash flow growth of 13% Embedding AI across portfolio and building common AI infrastructure to drive customer adoption and value Executing on our $2 billion share repurchase authorization: $200 million of repurchases in Q1'26; expect to use net after-tax proceeds from the Kepware and ThingWorx divestiture for incremental repurchases; targeting repurchases of ~$1.115 billion to ~$1.315 billion in FY'26 BOSTON, Feb. 4, 2026 /PRNewswire/ -- PTC (NASDAQ: PTC) today reported financial results for its first fiscal quarter ended December 31, 2025. "PTC delivered solid financial results in Q1'26, driven by large deal volume and competitive displacements.